Drug combinations and uses in treating a coughing condition
AssigneeInfirst Healthcare Limited
InventorsJohn Brew, Robin Mark Bannister
Life of this patent
Estimating the term…
Abstract
The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
Claims15
A method of treating a non-productive coughing condition, the method comprising the step of administering a therapeutically-effective amount of an oral pharmaceutical composition to an individual in need thereof, the oral pharmaceutical composition comprising 0.5 mg/mL to 10 mg/mL of Theobromine, 0.25 mg/mL to 7.5 mg/mL of Diphenhydramine, and 0.1 mg/mL to 5 mg/mL of Phenylephrine,
- wherein the pharmaceutical composition does not include a non-opiate antitussive agent,
- wherein the therapeutically-effective amount of the theobromine is at least 60 mg/day and at most 150 mg/day, and
- wherein administration reduces a symptom associated with the coughing condition.
A method of treating a non-productive coughing condition, the method comprising the step of administering a therapeutically-effective amount of an oral pharmaceutical composition to an individual in need thereof, the oral pharmaceutical composition comprising 0.5 mg/mL to 6 mg/mL of Theobromine, 0.25 mg/mL to 4 mg/mL of Diphenhydramine, and 0.1 mg/mL to 3 mg/mL of Phenylephrine,
- wherein the pharmaceutical composition does not include a non-opiate antitussive agent,
- wherein the therapeutically-effective amount of the theobromine is at most 250 mg/day, and
- wherein administration reduces a symptom associated with the coughing condition.
A method of treating a non-productive coughing condition, the method comprising the step of administering a therapeutically-effective amount of an oral pharmaceutical composition to an individual in need thereof, the pharmaceutical composition comprising 0.5 mg/mL to 4 mg/mL of Theobromine, 0.5 mg/mL to 3 mg/mL of Diphenhydramine, and 0.1 mg/mL to 2 mg/mL of Phenylephrine,
- wherein the pharmaceutical composition does not include a non-opiate antitussive agent,
- wherein the therapeutically-effective amount of the theobromine is at most 250 mg/day, and
- wherein administration reduces a symptom associated with the coughing condition.
Dependencies are inferred from the claim text.